OPTIRAY
As listed in the register: OPTIRAY 300 (300 mg l/mL), solution injectable en flacon
63,6 g · solution injectable
- Prescription only
- Active substance
- Ioversol
- Made by
- GUERBET
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Optiray 320). It describes the substance, not this exact product.
Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures until significant hemodilution occurs.
Ioversol may be visualized in the renal parenchyma within 30 to 60 seconds following rapid intravenous injection.
Greater than 95% of the administered dose was excreted in urine within the first 24 hours, with the peak urine concentration occurring in the first two hours after administration.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-29
Safety of the active substance
From the US prescribing label for the same active substance (Optiray 320). It describes the substance, not this exact product.
WARNING: NOT FOR INTRATHECAL USE Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions ( 5.1 )].
- Symptomatic hyperthyroidism.
- Symptomatic Hyperthyroidism ( 4 )
The most common reaction is nausea, occurring at a rate of 1 percent.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
Details
| Made by | GUERBET |
|---|---|
| Active substance | Ioversol |
| Strength | 63,6 g |
| Form | solution injectable |
| Route | intraartérielle;intraveineuse |
| Dispensing (as stated by the register) | liste I · médicament soumis à prescription médicale |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure nationale |
| Name in the register | OPTIRAY 300 (300 mg l/mL), solution injectable en flacon |
| Packs | 1 flacon(s) en verre de 500 ml · 1 flacon(s) en verre de 100 ml · 1 flacon(s) en verre de 200 ml · 10 flacon(s) en verre de 100 ml |
| CIS | 67722465 |
| CIP13 | 3400930282069 |
| CIP13 | 3400933276294 |
| CIP13 | 3400933276355 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution injectable2 products
- 63,6 g
- 74,2 g
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.